Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.
IPO Year:
Exchange: NASDAQ
Website: acastipharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/22/2021 | $6.00 | Outperform | Oppenheimer |
| 12/21/2021 | $6.00 | Outperform | Oppenheimer |
Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00
Oppenheimer initiated coverage of Acasti Pharma with a rating of Outperform and set a new price target of $6.00